Synthetic lethal effects of BMN 673 loaded solid lipid nanoparticles on triple-negative breast cancer

被引：0
|
作者：
Eskiler, G. Guney [1 ]
Cecener, G. [2 ]
Egeli, U. [2 ]
Tunca, B. [2 ]
机构：
[1] Sakarya Univ, Fac Med, Med Biol, Sakarya, Turkey
[2] Uludag Univ, Fac Med, Med Biol, Bursa, Turkey
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy314.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
75P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer
    Eskiler, Gamze Guney
    Cecener, Gulsah
    Egeli, Unal
    Tunca, Berrin
    PHARMACEUTICAL RESEARCH, 2018, 35 (11)
  • [2] Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer
    Gamze Guney Eskiler
    Gulsah Cecener
    Unal Egeli
    Berrin Tunca
    Pharmaceutical Research, 2018, 35
  • [3] Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer
    Llaguno-Munive, Monserrat
    Vazquez-Lopez, Maria Ines
    Garcia-Lopez, Patricia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [4] Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
    Eskiler, G. Guney
    Cecener, G.
    Egeli, U.
    Tunca, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Psoralen-loaded polymeric lipid nanoparticles combined with paclitaxel for the treatment of triple-negative breast cancer
    Liu, Fengjie
    Li, Lihong
    Lan, Meng
    Zou, Tengteng
    Kong, Zhaodi
    Cai, Tiange
    Wu, Xiaoyu
    Cai, Yu
    NANOMEDICINE, 2021, 16 (27) : 2411 - 2430
  • [6] Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
    Shu, Shaokun
    Wu, Hua-Jun
    Ge, Jennifer Y.
    Zeid, Rhamy
    Harris, Isaac S.
    Jovanovic, Bojana
    Murphy, Katherine
    Wang, Binbin
    Qiu, Xintao
    Endress, Jennifer E.
    Reyes, Jaime
    Lim, Klothilda
    Font-Tello, Alba
    Syamala, Sudeepa
    Xiao, Tengfei
    Chilamakuri, Chandra Sekhar Reddy
    Papachristou, Evangelia K.
    D'Santos, Clive
    Anand, Jayati
    Hinohara, Kunihiko
    Li, Wei
    McDonald, Thomas O.
    Luoma, Adrienne
    Modiste, Rebecca J.
    Quang-De Nguyen
    Michel, Brittany
    Cejas, Paloma
    Kadoch, Cigall
    Jaffe, Jacob D.
    Wucherpfennig, Kai W.
    Qi, Jun
    Liu, X. Shirley
    Long, Henry
    Brown, Myles
    Carroll, Jason S.
    Brugge, Joan S.
    Bradner, James
    Michor, Franziska
    Polyak, Kornelia
    MOLECULAR CELL, 2020, 78 (06) : 1096 - +
  • [7] MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
    Horiuchi, Dai
    Kusdra, Leonard
    Huskey, Noelle E.
    Chandriani, Sanjay
    Lenburg, Marc E.
    Gonzalez-Angulo, Ana Maria
    Creasman, Katelyn J.
    Bazarov, Alexey V.
    Smyth, James W.
    Davis, Sarah E.
    Yaswen, Paul
    Mills, Gordon B.
    Esserman, Laura J.
    Goga, Andrei
    JOURNAL OF EXPERIMENTAL MEDICINE, 2012, 209 (04): : 679 - 696
  • [8] Effects of Chitosan Nanoparticles with Long Synthetic siRNAs Targeting VEGF in Triple-Negative Breast Cancer Cells
    Comez, Birnur
    Akbuga, Juelide
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 59
  • [9] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile
    Eskiler, Gamze Guney
    Cecener, Gulsah
    Egeli, Unal
    Tunca, Berrin
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2019, 33 (05)
  • [10] Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery
    Rahdari, Tahereh
    Mahdavimehr, Mohsen
    Ghafouri, Hossein
    Ramezanpour, Sorour
    Ehtesham, Somayeh
    Asghari, S. Mohsen
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345